Michael Korzelius’ Post

SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments. At its heart, SynAI is about predicting the combined effects of cancer drugs, known as drug synergism. This AI-driven solution is trained with over 1.2 million in vitro tests across different cancer cell lines, flexible and innovative, focusing on early-stage drug discovery to identify the therapeutic potential of various compound combinations. Learn more about SynAI in the blog post. #CancerResearch #Oncology #DrugDiscovery #AI #Innovation #Bioscience #Biotech

Check this out! 👇 SynAI is an AI-driven platform designed to predict the synergistic effects of cancer drug combinations, poised to fundamentally change how we discover and evaluate cancer treatments. At its heart, SynAI is about predicting the combined effects of cancer drugs, known as drug synergism. This AI-driven solution is trained with over 1.2 million in vitro tests across different cancer cell lines, flexible and innovative, focusing on early-stage drug discovery to identify the therapeutic potential of various compound combinations. Learn more about SynAI in the blog post. #CancerResearch #Oncology #DrugDiscovery #AI #Innovation #Bioscience #Biotech

More promising news in the fight against cancer! UT MD ANDERSON CANCER CENTER and South Korean startup C-Biomex are co-developing a novel radiopharmaceutical, CBT-001, that can potentially transform cancer treatment. CBT-001 targets the CA9 (Carbonic anhydrase 9) biomarker overexpressed in kidney, breast and lung cancers. This strategic research partnership exemplifies how international cooperation can accelerate the advancement of life-saving therapies. What an exciting time for radiopharmaceutical innovation and the millions of people affected by cancer worldwide! https://lnkd.in/gUgMQzP6 #Radiopharmaceutical #Oncology #CancerResearch #GlobalCollaboration #cancertreatment 

Alentis has a new Chief Scientific Officer! Since Alberto Toso, PhD joined us in 2021, he has been instrumental in rapidly advancing anti-Claudin-1 antibodies (mAbs) and antibody-drug conjugates (ADCs) for oncology. Toso commented: “It is becoming increasingly clear that targeting Claudin-1 has tremendous potential for treating cancer. As CSO, it is my objective to harness the full potential of Claudin-1 with the development of ALE.P02 and ALE.P03, our anti-Claudin-1 ADCs, to benefit a wide range of cancer patients.” Read the full press release: https://lnkd.in/exttq9G8 #AlentisTherapeutics #Oncology #ChiefScientificOfficer #ADCs #Biotech

Cancer treatment is evolving, and at Immunai we're excited to play a key role in shaping its future. Immunai's new multi-year collaboration with AstraZeneca a aims to advance oncology clinical trials by leveraging our AI platforms, AMICA™, and the Immunodynamics Engine (IDE)™. We’re working together to gain deeper insights into patient responses, optimize dose selection, and identify key biomarkers for cancer treatment. Learn more about the collaboration from https://lnkd.in/dQNZ-u9e

We are pleased to announce that our AI-designed #molecularglue drug pipeline, MRANK-103, has successfully advanced to the IND-Enabling stage. This marks the fifth preclinical candidate (PCC) designated by 德睿智药 MindRank. Leveraging our AI-driven molecular glue rational design platform ProtaG™, MRANK-103 targets the #MYC signaling pathway and is designed to regulate eukaryotic translation and transcription factors.  This is a significant milestone in our fight against challenging cancers such as CDK4/6-resistant breast cancer, colorectal cancer, lung cancer, and gastric cancer—areas where current treatments are inadequate. We look forward to sharing more updates as we progress! #AI #artificialintelligence #DrugDiscovery #Oncology #Biotech #PrecisionMedicine #HealthcareInnovation

Arovella Therapeutics ASX: ALA has presented data characterising its CD19-targeting allogeneic #CellTherapy, ALA-101, at the prestigious American Association for Cancer Research (AACR) Annual Meeting in San Diego, USA. The data summarises two distinct phenotypes of cells within the drug product, each of which plays a different role in responding to #tumour cells. In particular, ALA-101 CAR-iNKT cells were separated based on whether or not they produced CD4 on their surface (CD4+ vs CD4-). Cells negative for CD4 (CD4-) were better able to kill target tumour cells via the CD19 Chimeric Antigen Receptor (CAR). In contrast, CD4+ cells proliferated faster in response to CD19+ tumour cells. The two groups of cells also produced a different cytokine response following CAR activation. More at #Proactive #ProactiveInvestors #ASX #ALA #Biotech #Biopharmaceutcials #Oncology #ImmunoOncology http://ow.ly/4lRm105oUBT

Like every year at this period, I am excited to see #InnatePharma participating in the #AACR2024 Annual Meeting, a not-to-be-missed event for cancer research community worldwide.   With more than 20,000 participants expected, our team is proud to have been selected to present in front of such a broad audience our lead proprietary Antibody Drug Conjugate (#ADC) IPH45. In a minisymposium oral session, Nicola Beltraminelli will present the “Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors” (abstract presentation #6582).   The promising preclinical results obtained underline the potential of IPH45, a novel and differentiated exatecan-based #Nectin-4 ADC with potential to improve clinical benefits across multiple tumor types.   The development of this product reflects our commitment at #Innate to pioneer the next wave of cancer treatments by creating differentiated next-generation antibody therapeutics.   We are eagerly advancing IPH45 towards clinical trials to bring new treatment options to cancer patients.   #InnatePharma #AACR2024 #Immunotherapy #oncology  

Yesterday was #WorldCancerDay, which aims to raise awareness of cancer and to encourage its prevention, detection, and treatment. Here, drug discovery experts weigh in on what to expect from cancer research and immunotherapies in 2024. https://lnkd.in/eGV2qgwR #WorldCancerDay2024 #Oncology

Apollomics presented vebreltinib data at the 2024 AACR meeting. Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer. Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting MET dysregulation, vebreltinib offers a potential breakthrough for many cancers driven by MET alterations. #QMportolio #QMhealthcare #cancertreatment #AACR #apollomics #clinicalstudy https://lnkd.in/gCsyHXaP